SEC Form 4 · accession 0001209191-16-149229
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandesh Mahatme
Officer — Senior Vice President, CFO
Period of report
Nov 9, 2016
Accepted (ET)
Nov 10, 2016 · 8:26 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 9, 2016 | M | 1,000 | $23.85 | A | 32,532 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F2 | $23.85 | Nov 9, 2016 | M | 1,000 | D | — | Nov 5, 2022 | Common Stock | 1,000 | 15,768 | D |
Explanation of responses
- F1Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million.
- F225% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire.